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Abstract
Background: Breast and prostate cancer patients often develop lesions of locally high bone
turnover, when the primary tumor metastasizes to the bone causing an abnormal high bone
resorption at this site. The objective of the present study was to determine whether local increased
bone turnover in breast and prostate cancer patients is associated with an increase in cartilage
degradation and to test in vitro whether osteoclasts or cathepsin K alone generate CTXII from
human bone.
Methods: The study included 132 breast and prostate cancer patient, where presence of bone
metastases was graded according to the Soloway score. Total bone resorption (CTXItotal) and
cartilage degradation (CTXII) were determined.
Results: Breast and prostate cancer patients with bone metastases revealed significant increased
levels of CTXItotal at Soloway scores 1 and higher compared to patients without bone metastases
(p < 0.001). CTXII was statistically elevated at score 3 and 4 (p < 0.01). CTXII/CTXItotal significantly
decreased at score 3 and 4 (p < 0.001). Levels of CTXItotal, CTXII and CTXII/CTXItotal changed
+900%, +130%, and -90%, respectively at Soloway score 4 compared to score 0. The in vitro
experiments revealed that osteoclasts released CTXI fragments but not CTXII from bone
specimens. The same was observed for cathepsin K.
Conclusion: Data suggest that an uncoupling between bone resorption and cartilage degradation
occurs in breast and lung cancer patient.
Background
Bone metastases are common in breast and prostate can-
cer patients causing an abnormal high bone remodeling at
these sites of metastasis destroying the bone structure.
Bone metastases occur in more than 50% of these patients
with advanced disease [1,2]. The pathology of bone
metastasis is characterized by a vicious cycle where the
equilibrium between the bone resorbing cells "osteo-
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clasts" and the bone forming cells "osteoblasts" is unbal-
anced causing highly elevated activity and number of cells
[2].
Bone and cartilage degradation can be measured in serum
and urine samples by biochemical markers such as bone
resorption by CTXI [3] and cartilage degradation by CTXII
[4]. These markers have been used extensively for the eval-
uation of these parameters in basic, pre-clinical and clini-
cal studies [5].
Anti-resorptive drugs have been shown to cause a decrease
in both cartilage degradation and bone resorption both in
postmenopausal women and Paget's disease patients [6-
8] indicating a coupling between the two processes. Type
II collagen has been identified in both the metaphysis and
diaphysis of rats [9], which was thought to be exclusively
expressed in cartilage, suggesting that part of the cartilage
degradation level could originate from the type II collagen
content in bone.
The aim of this study was to resolve whether the coupling
that has been observed between cartilage degradation and
bone resorption, is coupled in bone metastatic cancer
characterized by local high bone turnover. We have previ-
ously assessed eight different biochemical markers in a
group of breast, lung and prostate cancer patients [10]. In
the present study we compared the levels of cartilage deg-
radation as measured by CTXII to the levels of total bone
resorption (total CTXI) in a subset of this cohort. Addi-
tionally, we wanted to investigate whether CTXII could be
released from human bone specimens by osteoclasts in
vitro, bearing in mind that CTXII is present in the rat bone.
As the CTXII epitope might be destroyed by other enzy-
matic activities exhibited by the osteoclast we additionally
investigated the degradation of human bone by cathepsin
K alone.
Methods
Patients and study design
The cohort including a set of lung cancer patients has been
described elsewhere [10]. A total of 132 breast and pros-
tate cancer patients were referred to the Cancer Institute
Hospital, Tokyo between October 2002 and April 2004.
All patients underwent bone scanning using Technetium-
99 m scintigraphy together with computer tomography
and/or magnetic resonance imaging to verify and quantify
the presence of bone metastases (BM). The skeletal load
was graded, according to [11]. Soloway 0 refers to patients
without BM, Soloway 1 to patients with less than 6 BM,
Soloway 2 to patients with less than 20 BM, Soloway 3 to
patients with more than 20 but less than a "super scan",
Soloway 4 to patients with a "super scan" that is defined
by a more than 75% involvement of the ribs, vertebrae,
and pelvic bones.
Second void morning urine was collected from each
patient and stored at -40°C until assaying. All patients
with skeletal complications were newly diagnosed and
none had received therapies known to influence bone
turnover in the past 2 years prior to entry to the study. All
participants signed an approved written consent; the
study was done in accordance to the Helsinki Declaration
II and Standards of Good Clinical Practice. The Local Eth-
ical Committee had approved the study protocol.
Quantification of biochemical markers in the clinical study
Urine was used for estimation of bone resorption by
measuring the level of total CTXI (CTXItotal). The level of
cartilage degradation was assessed by measurement of
CTXII levels. The concentration of alpha CTX and beta
CTX fragments was measured by the urinary ALPHA
CrossLaps [12] and serum CrossLaps (urine samples were
diluted 1:25), respectively. Total CTXI was calculated as
the sum of alpha and beta CTXI. All assays were from Nor-
dic Bioscience, Herlev, Denmark and run according to
manufacturer's instructions. The ratio between CTXII and
total CTXI was calculated as CTXII/CTXItotal.
Human bone samples
Human cortical bones were collected during autopsy at
the Forensic Science Institute, Copenhagen, Denmark and
stored in 70% EtOH at 4°C. 2 cm long bone sticks from
one individual, were drilled from the central part of fem-
oral midshafts specimens. A stick was cut into 0.2 mm
thick slices with a diameter that fits into 96-well culture
plates. The Danish Ethical Committee had approved the
study (study no. KF01295491).
Human osteoclast precursors and differentiation on 
human cortical bone
The isolation of CD14+ monocytes was performed as pre-
viously described [13]. Briefly, human monocytes were
isolated from peripheral blood by centrifugation on a
Ficoll-Paque gradient (Amersham Pharmacia), and mag-
netically sorted using a CD14+ magnetic bead isolation
kit (Dynabeads M-450, Dynal Biotech). The cells were
then seeded in 75 cm2 flasks, and cultured in αMEM con-
taining 10% fetal calf serum, 100 U/mL penicillin, 100μg/
mL streptomycin, and 25 ng/ml of macrophage-colony
stimulating factor (M-CSF) (R&D Systems) for 3 days,
then they were lifted, re-seeded and cultured on human
cortical bone slices in the presence of 25 ng/ml M-CSF and
25 ng/ml receptor activator of NF-κB ligand (RANKL)
(R&D Systems) for 28 days. Conditioned medium was
collected every second or third day.
Cathepsin K degradation of human cortical bone
Human cortical bone slices were decalcified for 4 days at
4°C by ethylenediamine tetraacetic acid (EDTA) (0.5
mol/L EDTA, 0.05 mol/L Tris, 1% NaN3, pH 7.5) andBMC Cancer 2008, 8:180 http://www.biomedcentral.com/1471-2407/8/180
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washed in MilliQ-water. Bone slices of 4.4 mg were snap-
frozen in liquid nitrogen and pulverized using a Bessman
tissue pulverizer (Spectrum, The Netherlands). 750 μg
bone powder was transferred to eppendorfh tubes and
mixed with 650 μL cathepsin K buffer (50 mM Na-Acetat,
20 mM L-Cystine, pH 5.5), homogenized 1/2–1 min.
using a Polytron homogenizer at speed level 5. Recom-
binant human cathepsin K (Calbiochem, cat. no. 342001)
was activated as recommended by manufacturer and 17
μL 100 μg/mL activated cathepsin K or control was added
to 100 μL bone powder mixture. Samples were incubated
overnight at 37°C and centrifuged at 1700 × g for 10 min-
utes; supernatants were harvested and centrifuged again at
10,000 × g.
Quantification of biochemical markers in the in vitro 
studies
Levels of CTXI and CTXII fragments were assessed in the
conditioned medium using CrossLaps for culture (beta
CTX) and urinary Pre-Clinical CartiLaps (CTXII), respec-
tively. Both were from Nordic Bioscience, Herlev, Den-
mark and run according to manufacturer's instructions.
Statistical Analysis
The values of each of the biochemical markers were loga-
rithmically transformed to obtain normality. Comparison
of the levels at each Soloway score relative to Soloway
score 0 was performed by analysis of variance (ANOVA)
using the General Linear Models Procedure of the Statisti-
cal Analysis System (SAS, Cary, NC). Differences and asso-
ciations were considered statistically significant if p <
0.05.
Results
Relation to the extent of metastatic bone disease
Demographic data has been published elsewhere [10].
There were no statistically significant differences in age,
BMI and sex distribution between the patients with or
without BM.
The levels of CTXII, CTXItotal and CTXII/CTXItotal were
stratified according to the extent of metastatic disease
(Soloway score) and data are shown in table 1. CTXItotal
was highly elevated at all Soloway scores (p < 0.001) com-
pared to score 0. CTXII was statistically significantly ele-
vated at Soloway score 3 and 4 (p < 0.01). In contrast, the
ratio CTXII/CTXItotal decreased significantly at Soloway
scores 3 and 4 (p < 0.001) compared to score 0. Levels of
CTXIbeta representing the general bone resorption exhib-
ited the same pattern as CTXItotal with significant elevation
at all Soloway scores (score 1: p < 0.05; score 3, 4: p <
0.001) and the ratio CTXII/CTXIbeta  significantly
decreased at score 4 (p < 0.001) (data not shown).
The level of each marker was calculated relative to the
marker level at Soloway score zero. Figure 1 shows the
association between Soloway score and markers. It was
seen that CTXItotal clearly increased with extent of meta-
static disease; the percentage increase at score 1 was 70%
and highest at score 4 presenting a 900% increase. CTXII
was elevated at Soloway score 3 with 100% and at score 4
with a 130% increase. The levels of the ratio CTXII/CTXI-
total decreased 50% at score 3 and 80% at score 4. Beta
CTXI decreased 60% at score 1 and 620% at score 4 (data
not shown)
Osteoclasts release CTXI but not CTXII from human bone
Human osteoclast precursors were seeded on human
bone slices and cultured for 28 days in the presence of
RANKL and M-CSF for differentiation and resorption.
CTXI and CTXII were assessed in the conditioned medium
collected at all time points.
During day 1–8 osteoclast precursors had to differentiate
into mature osteoclasts thus the level of CTXI and CTXII
was zero. After day 8 it was seen that mature osteoclasts on
human bone were able to resorb and release CTXI frag-
ments but not CTXII fragments, as previously described
on bovine bones [14]. Data on figure 2 shows the level of
CTXI and CTXII in the conditioned medium collected at
day 28, representing the pattern seen throughout day 9–
28.
Table 1: Mean marker levels in cancer patients stratified by Soloway Score
Soloway score
0 123 4
n 70 26 13 15 8
CTXItotal μg/mmol (1 SD range) 1.65 (0.88–1.88) 2.79*** (1.54–3.41) 3.84*** (1.84–3.54) 6.64*** (3.21–6.22) 16.49*** (7.67–14.35)
CTXII μg/mmol (1 SD range) 0.18 (0.09–0.18) 0.23 (0.11–0.19) 0.25 (0.14–0.31) 0.36** (0.22–0.57) 0.41** (0.28–0.85)
CTXII/CTXtotal (1 SD range) 0.11 (0.05–0.11) 0.08ns (0.04–0.08) 0.07ns (0.04–0.11) 0.05*** (0.04–0.11) 0.03*** (0.02–0.04)
Cancer type (n) 44 BC, 26 PC 20 BC, 6 PC 12 BC, 1 PC 12 BC, 3 PC 5 BC, 3 PC
SD = Standard Deviation, BC = Breast Cancer, PC = Prostate Cancer. * indicates significant difference between the Soloway score compared to 
score 0.BMC Cancer 2008, 8:180 http://www.biomedcentral.com/1471-2407/8/180
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Cathepsin K release of CTXI and CTXII from human bone
From figure 3 it is seen that the release of CTXI was only
observed from the positive control; human bone treated
with cathepsin K. Release of CTXII fragments by cathepsin
K was not observed from bone.
Discussion
We performed a comparison of bone resorption (CTXI)
and cartilage degradation (CTXII) in a cohort of breast
and prostate cancer patients stratified by the number of
bone metastases to investigate whether the coupling
between bone and cartilage degradation observed in post-
menopausal women and Paget's patients is uncoupled in
these cancer patients. The main findings were as follows:
1) CTXItotal  was significantly increased at all Soloway
scores as was expected for a collagenous bone degradation
marker, 2) CTXII was not significantly elevated until at
Soloway score 3, where progression of the disease had
reached to more than 20 bone metastases, 3) The ratio
CTXII/CTXItotal decreased with extent of metastatic dis-
ease, showing that the molar ratio of CTXI and CTXII frag-
ments did not follow the same pattern of release through
disease progression, 4) Mature osteoclasts resorbing on
human cortical bone in an in vitro model was not able to
CTXII fragments, 5) and cathepsin K degradation of
human bone in vitro did not result in generation of CTXII
fragments.
Uncoupling of bone and cartilage degradation
Our data show that there is an uncoupling between degra-
dation of bone and cartilage in metastatic breast and pros-
tate cancer. Bone resorption increased in the group of
patients that were in the initial phase of developing bone
metastases having one to six bone metastases. Cartilage
degradation was not elevated parallel to high bone resorp-
tion levels until at a late stage in the pathology of the can-
cer invasion involving multiple skeletal lesions. This
disassociation of localized bone resorption and cartilage
degradation in early stages of cancer patients with bone
metastases suggests bone turnover alone is not the cause
of the association of bone resorption and cartilage turno-
ver.
Bone and cartilage turnover is coupled during some sys-
temic pathologies such as postmenopausal osteoporosis
and osteoarthritis. In response to estrogen supplementa-
tion or some anti-resorptives a reduction in both bone
and cartilage degradation is observed, providing both a
bone and cartilage sparring effect. We hypothesized that
secondary to the increased bone resorption in case of
patients having bone metastasis, an increased cartilage
degradation would be observed additional to an even
longer list of secondary complications and thereby reduc-
Release of CTXI and CTXII from cathepsin K treated human  cortical bone Figure 3
Release of CTXI and CTXII from cathepsin K treated human 
cortical bone.
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Release of CTXI and CTXII by osteoclastic resorption of  human cortical bone at day 28 Figure 2
Release of CTXI and CTXII by osteoclastic resorption of 
human cortical bone at day 28.
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Relative increases in bone and cartilage degradation markers  and ratio between these as a function of the extent of skele- tal involvement assessed in 132 breast and prostate cancer  patients Figure 1
Relative increases in bone and cartilage degradation markers 
and ratio between these as a function of the extent of skele-
tal involvement assessed in 132 breast and prostate cancer 
patients. Relative increases are expressed as percentage of 
levels in patients with Soloway score 0. Asterisks indicate sig-
nificant difference compared to the level at score 0.
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ing the quality of life. This was not the case and no treat-
ment is needed for cartilage degradation. Thus, whereas
systemic increased bone resorption resulted in secondary
cartilage erosions, local increased bone turnover did not
result in cartilage degradation.
Detection of bone metastases has been demonstrated for
a number of biomarkers in prostate and breast cancer
cohorts [15,10,16-21] in which it generally seems that col-
lagenous markers are some of the best discriminators.
However, no one has investigated cartilage degradation
markers. Thus this is the first study to demonstrate that
cartilage degradation does not correlate to number of
bone metastases in prostate and breast cancer patients
until patients reach a disease stage where they have more
than 20 bone metastases. At this point, the progression of
the disease is at a phase that might be aggressive enough
to affect the joints of these patients or alternatively caused
by a secondary affect from cancer treatment regimens or
high expression of various cytokines by the cancer cells.
However, these observations need further experimental
data to be carefully investigated.
Cathepsin K degradation of human bone
Cathepsin K is the most abundant collagenolytic protease
of the osteoclast [22]. We investigated whether cathepsin
K alone or the protolytic capacity of osteoclasts including
cathepsin K, were capable of generating CTXII fragments
in simple in vitro systems.
The in vitro data demonstrated that neither resorbing oste-
oclasts nor cathepsin K alone were able to generate CTXII
fragments from human bone. In rats, collagen type II in
present in some part of cortical bone, although the molar
ratios of collagen type I to II remains to be investigated
[9]. We used human cortical bone and clearly demon-
strated with sensitive ELISA assays that CTXII cannot be
released by cathepsin K alone or osteoclasts from bone.
These findings either suggest that collagen type II is not
present in human bone, or that cathepsin K cannot gener-
ate the CTX-II epitope. In addition, the vast proteolytic
machinery of the osteoclast may destroy the CTX-II
epitope if generated.
Conclusion
Our data suggest that an uncoupling between bone and
cartilage degradation occurs in these cancer patients with
bone metastases. Thus the coupling observed in other dis-
ease groups can be disassociated and that cartilage degra-
dation is not of concern for these patients. We clearly
demonstrate that osteoclasts or cathepsin K alone are not
able to generate CTXII fragments from human bone in
vitro, suggesting that clinical CTX-II originate from carti-
lage.
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